Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
10 mg | 在庫あり | ¥ 8,000 | |||
25 mg | 在庫あり | ¥ 13,000 | |||
50 mg | 在庫あり | ¥ 21,500 | |||
100 mg | 在庫あり | ¥ 35,500 | |||
500 mg | 在庫あり | ¥ 89,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 7,500 |
説明 | Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis. |
別名 | DE-019, Thiobutarit, Tiobutarit, SA96, DE 019, DE019 |
分子量 | 223.31 |
分子式 | C7H13NO3S2 |
CAS No. | 65002-17-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (111.95 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bucillamine 65002-17-7 Angiogenesis oxidation-reduction Tyrosine Kinase/Adaptors VEGFR Antioxidant rheumatoid arthritis DE-019 Thiobutarit Ischemia/reperfusion Tiobutarit antioxidant antirheumatic inhibit Inhibitor SA96 SA-96 DE 019 antiangiogenic SA 96 Vascular endothelial growth factor receptor choroidal neovascularization DE019 inhibitor